Pharmaceutical

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it is enrolling patients in a multicenter Phase 1/1b clinical trial of CPI-006, a humanized monoclonal antibody directed against CD73. As quoted in the press release: The three-arm study in patients with a variety …

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it is enrolling patients in a multicenter Phase 1/1b clinical trial of CPI-006, a humanized monoclonal antibody directed against CD73.

As quoted in the press release:

The three-arm study in patients with a variety of solid tumors is evaluating CPI-006 administered as a single agent, in combination with Corvus’ CPI-444, a selective and potent inhibitor of the adenosine A2A receptor, and in combination with pembrolizumab, an anti-PD-1 antibody.

“CPI-006 is an antibody engineered to completely inhibit the CD73 enzyme by binding to its active site. We look forward to evaluating this anti-CD73 antibody in our comprehensive Phase 1/1b trial, which we believe is the first human clinical trial in oncology to evaluate the effect of dual-blockade of the adenosine pathway by inhibiting both CD73 and the A2A receptor,” said Richard A. Miller, M.D., an oncologist and co-founder, president and chief executive officer of Corvus. “This trial is designed to answer multiple important questions regarding the role of CD73 blockade and the adenosine pathway in patients with advanced cancer. With the initiation of this new trial and our ongoing Phase 1/1b clinical trial of CPI-444, we continue to reinforce our leadership position in this new therapeutic area.”

Click here to read the full press release.

MARKETS

Markets
TSX19991.88+105.94
TSXV673.02+3.30
DOW33336.67+27.16
S&P 5004207.27-2.97
NASD12779.91-74.89
ASX7071.00+78.30

COMMODITIES

Commodities
Gold1787.48-1.50
Silver20.31+0.04
Copper3.69-0.01
Palladium2270.50-5.50
Platinum957.00+2.00
Oil94.55+0.21
Heating Oil3.53+0.05
Natural Gas8.65-0.23

DOWNLOAD FREE REPORTS

×